Beijing SL Pharmaceutical Lamivudine Receives Approval
This article was originally published in PharmAsia News
Executive Summary
Beijing SL Pharmaceutical has received a production license and new drug certification for its lamivudine capsule and lamivudine raw material for treating the hepatitis B virus. At present, TIPR Pharmaceutical's Daiding ranks top in China's lamivudine market with 57.75 percent, and GSK's Heptodin accounting for the remaining market share. According to estimates, hospitals in the country spend RMB 480 million on lamivudine and the drug will hit RMB 1 billion in revenue by 2010. Beijing SL believes that few companies have the capability to produce the drug, and supply still lags behind demand. It is thus optimistic about the potential of the product and will go into production soon. (Click here for more - Chinese Language)
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.